KalVista PharmaceuticalsKALV
Market Cap: $475M
About: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Employees: 150
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
36% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 33
1.95% more ownership
Funds ownership: 112.38% [Q1] → 114.33% (+1.95%) [Q2]
1% more capital invested
Capital invested by funds: $562M [Q1] → $568M (+$5.95M) [Q2]
7% less funds holding
Funds holding: 128 [Q1] → 119 (-9) [Q2]
15% less call options, than puts
Call options by funds: $373K | Put options by funds: $441K
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
32% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 28
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 167 met price target | 82%upside $20 | Buy Reiterated | 6 Sept 2024 |
Needham Serge Belanger 50% 1-year accuracy 58 / 115 met price target | 191%upside $32 | Buy Reiterated | 6 Sept 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 167 met price target | 82%upside $20 | Buy Reiterated | 15 Jul 2024 |
Needham Serge Belanger 50% 1-year accuracy 58 / 115 met price target | 191%upside $32 | Buy Maintained | 12 Jul 2024 |
Financial journalist opinion
Based on 7 articles about KALV published over the past 30 days